Health-care workers (HCW) are at high risk for SARS-CoV-2 infection and, if asymptomatic, for transmitting the virus to fragile cancer patients. We monitored all asymptomatic HCWs of a cancer institute (94% of all employees agreed to enter the study) with the rapid serological test, VivaDiag TM , identifying SARS-CoV-2 associated-IgM/IgG. The tests were performed at time 0 ( n = 606) and after 14 days ( n = 393). Overall, the VivaDiag TM results of nine HCWs (1.5%) were positive, with one confirmed to be SARS-CoV-2-positive after oropharyngeal swab testing by RT-PCR. At time 0, all nine cases showed IgM expression while IgG was detected in only one. After 14 days, IgM persisted in all the cases, while IgG became evident in four. A chemiluminescence immunoassay (CLIA) confirmed IgM positivity in 5/13 VivaDiag TM positive cases and IgG positivity in 4/5 VivaDiag TM positive cases. Our study suggests that the VivaDiag TM test can be of help in identifying SARS-CoV-2 infected people in cohorts of subjects with a high prevalence.
【저자키워드】 COVID-19, serological test, SARS-CoV-2, Health-care workers, Cancer center, 【초록키워드】 CLIA, IgG, IgM, SARS-COV-2 infection, Cancer, RT-PCR, virus, Prevalence, Cohort, Asymptomatic, oropharyngeal swab, chemiluminescence immunoassay, Cancer patients, expression, high risk, HCW, subject, help, IgG positivity, positive, performed, nine, 【제목키워드】 Test, Screening, Prospective, Rapid, monitoring, worker, center,